Edition:
United States

Stemline Therapeutics Inc (STML.OQ)

STML.OQ on NASDAQ Stock Exchange Capital Market

17.80USD
15 Jun 2018
Change (% chg)

-- (--)
Prev Close
$17.80
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
80,068
52-wk High
$20.55
52-wk Low
$7.30

Chart for

About

Stemline Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the... (more)

Overall

Beta: 0.16
Market Cap(Mil.): $538.88
Shares Outstanding(Mil.): 30.27
Dividend: --
Yield (%): --

Financials

  STML.OQ Industry Sector
P/E (TTM): -- 240.92 34.18
EPS (TTM): -2.96 -- --
ROI: -79.02 -5.87 13.17
ROE: -79.10 -7.71 15.15

BRIEF-Stemline Therapeutics Reports Q1 Loss Per Share $0.69

* STEMLINE THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

May 09 2018

Stemline Therapeutics wins dismissal of shareholder lawsuit

A federal judge has dismissed a lawsuit accusing Stemline Therapeutics Inc of misleading investors about its ability to address the risk of a fatal side effect associated with a drug it was developing to treat certain blood-related cancers.

Mar 16 2018

BRIEF-Stemline Therapeutics Inc - Co Launched An At-Market Offering Of Up To $50 Million Worth Of Shares

* STEMLINE THERAPEUTICS INC - ‍ON MARCH 16, 2018, CO LAUNCHED AN AT--MARKET OFFERING OF UP TO $50 MILLION WORTH OF SHARES OF COMPANY'S COMMON STOCK​ Source text (http://bit.ly/2HHHaYN) Further company coverage: (Reuters.Brief@thomsonreuters.com)

Mar 16 2018

BRIEF-Stemline Therapeutics Q4 Loss Per Share $0.93

* STEMLINE THERAPEUTICS REPORTS FOURTH QUARTER 2017 FINANCIAL RESULTS

Mar 16 2018

BRIEF-Stemline Therapeutics Prices $51.8 Mln Public Offering

* STEMLINE THERAPEUTICS PRICES $51.8 MILLION PUBLIC OFFERING OF COMMON STOCK

Jan 24 2018

BRIEF-Stemline Therapeutics Announces Proposed Public Offering Of Common Stock

* STEMLINE THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

Jan 22 2018

Competitors

Earnings vs. Estimates